Close Menu

University of Oxford

Eisai will use Genomics' tools in its drug R&D efforts including for target selection, validation, and more.

Using samples from more than 2,000 people in the UK, an international team of researchers examined the pattern of genetic variation across the UK as well as continental European contributions to UK ancestry.

The consortium will address the major scientific challenges involving the productivity and sustainability of both natural and managed forests.

The grant will support a one-year pilot project to create a comprehensive map of human genetic variation for biomedical research.

The RNAi-based drug is designed to specifically target the strain of the virus responsible for the current outbreak.

The consortium comprises Oxford BioDynamics,OxfordUniversityresearchers, and Chronos Therapeutics.

The University of Oxford spinout is developing a platform for genomic sequence data analysis.

NEW YORK (GenomeWeb) – VolitionRx today announced a collaboration with the University of Oxford on a clinical study to develop biomarkers for the diagnosis of endometriosis using the firm's Nucleosomics platform.

NEW YORK (GenomeWeb News) – The University of Oxford today announced the launch of the Precision Cancer Medicine Institute, a center that will use genomics and molecular diagnostics, among other technologies, to carry out research into cancer therapies.

NEW YORK (GenomeWeb) – The Chan Soon-Shiong Institute for Molecular Medicine is teaming up with the University of Oxford to form a new institute in the UK that will support individualized, data-driven molecular medicine for cancer patients.

Pages

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.